Lymphoma, Large B-Cell, Diffuse: all 1,432 studies
Page 10 of 15. Open to participants first (358), then studies with results posted, then the rest; newest registration first within each.
- Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported OutcomesCompletedNCT04319237
- A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T TherapyCompletedNCT04316624Phase 1
- Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTerminatedNCT04305444Phase 2
- Diet, Physical Activity and Body Composition Changes During R-CHOPWithdrawnNCT04293900
- Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT04285268Phase 2
- A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLWithdrawnNCT04279938Phase 1
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedNCT04279405Phase 1
- Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCLCompletedNCT04263584Phase 2
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
- Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)Status unknownNCT04237168
- Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaActive, not recruitingNCT04231877Phase 1/2
- A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04231747Phase 1
- Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCLCompletedNCT04231448Phase 3
- Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
- Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell LymphomaStatus unknownNCT04215016Phase 1
- R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell LymphomaCompletedNCT04214626Phase 2
- Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With RituximabCompletedNCT04214444Phase 3
- Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell LymphomaTerminatedNCT04205838Phase 2
- Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell LymphomaStatus unknownNCT04183569
- Study of LUCAR-20S in Patients With R/R NHLTerminatedNCT04176913Phase 1
- Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma PatientsCompletedNCT04164368Phase 2
- Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FLCompletedNCT04160442Not applicable
- Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
- Lenalidomide Monotherapy in R/R DLBCLCompletedNCT04150328
- Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT04113226Phase 2
- ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell LymphomaStatus unknownNCT04112238
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins LymphomaActive, not recruitingNCT04089215Phase 2
- Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell LymphomaCompletedNCT04067414Phase 1
- QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell LymphomaWithdrawnNCT04052061Phase 1
- A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCLCompletedNCT04049825Phase 1
- ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)Active, not recruitingNCT04049513Phase 1
- CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaStatus unknownNCT04026100Phase 1
- Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
- Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Status unknownNCT04023916Phase 2
- Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCLCompletedNCT04022005Phase 2
- GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCLStatus unknownNCT04021992Phase 2
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)CompletedNCT04018248Phase 1
- Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaActive, not recruitingNCT04007029Phase 1
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnNCT03999658Phase 2
- Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingNCT03995147Phase 2
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasActive, not recruitingNCT03984448Phase 2/3
- Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/ProgressionStatus unknownNCT03977623
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive, not recruitingNCT03960840Phase 1/2
- Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic MalignanciesCompletedNCT03955783Phase 1
- Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedNCT03939182Phase 1
- A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
- Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruitingNCT03888105Phase 2
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesCompletedNCT03886831Phase 1
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1
- Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
- A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT03873025Phase 1/2
- Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaTerminatedNCT03864419Phase 1
- Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma PatientsWithdrawnNCT03850028Not applicable
- Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for LymphomaActive, not recruitingNCT03843294Phase 1
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow TransplantationActive, not recruitingNCT03842696Phase 1/2
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)CompletedNCT03833180Phase 1
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- Early Palliative Care for Patients With Haematological MalignanciesStatus unknownNCT03800095Phase 3
- A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
- Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell LymphomaStatus unknownNCT03797170
- Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
- Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03777085Phase 3
- Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT03749018Phase 2
- Acalabrutinib Plus RICE for Relapsed/Refractory DLBCLStatus unknownNCT03736616Phase 2
- Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.Status unknownNCT03720457Phase 1
- Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaStatus unknownNCT03719989Phase 2
- Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell LymphomaWithdrawnNCT03719560Phase 2
- Lenalidomide Based Immunotherapy in the Treatment of DLBCLStatus unknownNCT03715296
- Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaSuspendedNCT03704714Phase 1/2
- A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaCompletedNCT03688152Phase 1
- Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell LymphomaCompletedNCT03682796Phase 1
- Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell LymphomaCompletedNCT03677154Phase 1/2
- A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03670901Phase 3
- Refractory Diffuse Large B-cell LymphomaCompletedNCT03664336
- Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell LymphomaActive, not recruitingNCT03656835Not applicable
- AEDV Registry of Primary Cutaneous LymphomaStatus unknownNCT03646422
- Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1
- Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma SubjectsStatus unknownNCT03629873Phase 2
- A Trial of Radiotherapy and Durvalumab in DLBCL and FLCompletedNCT03610061Phase 1
- A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma PatientsStatus unknownNCT03600363Phase 2
- Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell LymphomasWithdrawnNCT03586024Phase 1/2
- CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaWithdrawnNCT03579927Phase 1/2
- CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
- A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT03579082Phase 4
- Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT03576443Phase 2
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT03571308Phase 1/2
- Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
- A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLTerminatedNCT03547115Phase 1
- PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLCompletedNCT03543813Phase 1/2
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
- RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis FactorCompletedNCT03536039Phase 2
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
- Treatment of Elderly Patients With Diffuse Large B-cell LymphomaStatus unknownNCT03513601Phase 4
- RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell LymphomaCompletedNCT03485118Phase 2
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingNCT03479268Phase 1